ACTA1 and cancer: Concurrently, restoring activin type IIA receptor in mutated malignant enterocytes provoked smad4-dependent cell cycle arrest and apoptosis, implying that cancerous cells could bypass the Act-A anti-cancer actions by developing mutations in the Acvr2a or Smad4 genes [14, 15].